These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 2528741)

  • 1. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
    Waxman J
    Prog Clin Biol Res; 1989; 303():61-8. PubMed ID: 2528741
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyproterone acetate in the management of prostatic cancer.
    Tunn UW
    Prog Clin Biol Res; 1989; 303():105-10. PubMed ID: 2528734
    [No Abstract]   [Full Text] [Related]  

  • 3. [A 79-year-old man with metastatic prostate cancer, treated with Zoladex, flutamide, calcitonin and Ostac, suffers from frequent troublesome sweating with palpitation and angina pectoris, especially at night. Is there a therapy?].
    Schmeller N
    Internist (Berl); 1992 Apr; 33(4):284. PubMed ID: 1535344
    [No Abstract]   [Full Text] [Related]  

  • 4. Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
    Habenicht UF; Schröder H; el Etreby MF; Neumann F
    Prog Clin Biol Res; 1988; 260():63-75. PubMed ID: 2966407
    [No Abstract]   [Full Text] [Related]  

  • 5. Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
    Di Silverio F; Sciarra F; D'Eramo G
    Eur Urol; 1990; 18(1):10-5. PubMed ID: 2144819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation of LHRH monotherapy for prostate cancer.
    Milsted RA
    Prog Clin Biol Res; 1989; 303():69-74. PubMed ID: 2528742
    [No Abstract]   [Full Text] [Related]  

  • 7. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
    Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
    [No Abstract]   [Full Text] [Related]  

  • 8. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New forms and future perspectives in endocrine treatment of prostatic carcinoma.
    Jacobi GH; Wenderoth UK
    Prog Clin Biol Res; 1984; 153():529-45. PubMed ID: 6236463
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
    Schulze H; Senge T
    J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
    Waxman J; Williams G; Sandow J; Hewitt G; Abel P; Farah N; Fleming J; Cox J; O'Donoghue EP; Sikora K
    Am J Clin Oncol; 1988; 11 Suppl 2():S152-5. PubMed ID: 2853934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer.
    Moffat LE
    Eur Urol; 1990; 18 Suppl 3():26-7. PubMed ID: 2151272
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
    Spitz IM; Chertin B; Lindenberg T; Farkas A
    N Engl J Med; 1999 May; 340(18):1439. PubMed ID: 10328706
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V; al-Abadi H; Nagel R
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer of the prostate. Mechanisms of action of antiandrogens.
    Habenicht UF; Neumann F; el Etreby MF
    Acta Urol Belg; 1991; 59(4):1-10. PubMed ID: 1840231
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cyproterone acetate and cancer of the prostate. Experience in 46 cases].
    Tauveron I; Hermabessière J
    Therapie; 1988 May; 43(3):175-7. PubMed ID: 2971277
    [No Abstract]   [Full Text] [Related]  

  • 17. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW; Uitterlinden P; de Jong FH
    Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
    Denis L; Keuppens F; Mahler C; Debruyne FM; Weil EH; Lunglmayr G; Newling D; Robinson MR; Richards B; Smith PH
    Prog Clin Biol Res; 1987; 243A():221-7. PubMed ID: 2958852
    [No Abstract]   [Full Text] [Related]  

  • 19. [Lack of effect of therapy with LHRH analogs, alone or associated with flutamide, on prolactin levels in advanced prostatic carcinoma].
    Banchini A; Zavaroni D; Tarditi E; Cortellini P; Ziveri M; Polotti R; Stefani F; Valenti G
    Minerva Endocrinol; 1989; 14(3):165-8. PubMed ID: 2533662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newer methods of hormonal therapy for prostate cancer.
    Soloway MS
    Urology; 1984 Nov; 24(5 Suppl):30-8. PubMed ID: 6437034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.